Alzheimer's disease (AD) - Pipeline Insight, 2020
This report can be delivered to the clients within 5 Business Days
DelveInsight’s, “Alzheimer’s Disease (AD) – Pipeline Insight, 2020,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Alzheimer’s Disease (AD) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Alzheimer’s Disease (AD): Overview
Alzheimer’s Disease (AD) is a slowly progressive brain disease that begins many years before symptoms emerge. It is the most common cause of dementia, accounting for an estimated 60% to 80% of cases. The hallmark pathologies of Alzheimer's disease are the accumulation of the protein fragment beta?amyloid (plaques) outside neurons in the brain and twisted strands of the protein tau (tangles) inside neurons. These changes are accompanied by the death of neurons and damage to brain tissue. On the basis of severity, this degenerative disease can be classified as mild, moderate, and severe.
Symptoms
Alzheimer’s disease is a progressive condition therefore the symptoms get worse over time. Memory loss is a key feature, and this tends to be one of the first symptoms to develop. Other symptoms are:
A diagnosis of Alzheimer’s Disease (AD) is made based upon a thorough clinical evaluation, a detailed patient history, and a variety of specialized tests. Means of diagnosing AD include clinical diagnosis which is usually made during the mild stage of the disease, Lumbar puncture, and Imaging studies.
Treatment
Treatment for Alzheimer’s Disease (AD) includes options that may reduce the symptoms and help improve the quality of life. The U.S. Food and Drug Administration (FDA) has approved two types of medications — cholinesterase inhibitors (Aricept, Exelon, Razadyne) and memantine (Namenda) to treat the cognitive symptoms. Other non-pharmacological therapies are also used with the goal of maintaining or improving cognitive function, the ability to perform activities of daily living or overall quality of life.
Alzheimer’s Disease (AD) Emerging Drugs Chapters
This segment of the Alzheimer’s Disease (AD) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Alzheimer’s Disease (AD) Emerging Drugs
Further product details are provided in the report
Alzheimer’s Disease (AD): Therapeutic Assessment
This segment of the report provides insights about the different Alzheimer’s Disease (AD) drugs segregated based on following parameters that define the scope of the report, such as:
Alzheimer’s Disease (AD): Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Alzheimer’s Disease (AD) therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Alzheimer’s Disease (AD) drugs.
Report Highlights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Alzheimer’s Disease (AD) – Pipeline Insight, 2020,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Alzheimer’s Disease (AD) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Alzheimer’s Disease (AD): Overview
Alzheimer’s Disease (AD) is a slowly progressive brain disease that begins many years before symptoms emerge. It is the most common cause of dementia, accounting for an estimated 60% to 80% of cases. The hallmark pathologies of Alzheimer's disease are the accumulation of the protein fragment beta?amyloid (plaques) outside neurons in the brain and twisted strands of the protein tau (tangles) inside neurons. These changes are accompanied by the death of neurons and damage to brain tissue. On the basis of severity, this degenerative disease can be classified as mild, moderate, and severe.
Symptoms
Alzheimer’s disease is a progressive condition therefore the symptoms get worse over time. Memory loss is a key feature, and this tends to be one of the first symptoms to develop. Other symptoms are:
- Cognitive deficits.
- Problems with recognition
- Problems with spatial awareness
- Problems with speaking, reading, or writing
- Later symptoms include impaired communication, disorientation, confusion, poor judgment, behavioral changes and, ultimately, difficulty speaking, swallowing and walking.
- As the disease progresses, neurons in other parts of the brain are damaged or destroyed.
A diagnosis of Alzheimer’s Disease (AD) is made based upon a thorough clinical evaluation, a detailed patient history, and a variety of specialized tests. Means of diagnosing AD include clinical diagnosis which is usually made during the mild stage of the disease, Lumbar puncture, and Imaging studies.
Treatment
Treatment for Alzheimer’s Disease (AD) includes options that may reduce the symptoms and help improve the quality of life. The U.S. Food and Drug Administration (FDA) has approved two types of medications — cholinesterase inhibitors (Aricept, Exelon, Razadyne) and memantine (Namenda) to treat the cognitive symptoms. Other non-pharmacological therapies are also used with the goal of maintaining or improving cognitive function, the ability to perform activities of daily living or overall quality of life.
Alzheimer’s Disease (AD) Emerging Drugs Chapters
This segment of the Alzheimer’s Disease (AD) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Alzheimer’s Disease (AD) Emerging Drugs
- BAN2401: Eisai
- Gantenerumab: Hoffmann-La Roche
Further product details are provided in the report
Alzheimer’s Disease (AD): Therapeutic Assessment
This segment of the report provides insights about the different Alzheimer’s Disease (AD) drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Alzheimer’s Disease (AD)
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravitreal
- Subretinal
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Alzheimer’s Disease (AD): Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Alzheimer’s Disease (AD) therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Alzheimer’s Disease (AD) drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Alzheimer’s Disease (AD) R&D. The therapies under development are focused on novel approaches to treat/improve Alzheimer’s Disease (AD).
- In December 2019, BioArctic announced the initiation of a research collaboration with Eisai aimed at further studying the unique profile of the investigational drug candidate BAN2401. The research collaboration with Eisai is in addition to the existing development and commercialization agreement for BAN2401. This new collaboration is intended to further characterize the unique binding profile of BAN2401.
- Alzheimer’s Disease (AD) Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Alzheimer’s Disease (AD) drugs?
- How many Alzheimer’s Disease (AD) drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Alzheimer’s Disease (AD)?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Alzheimer’s Disease (AD) therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Alzheimer’s Disease (AD) and their status?
- What are the key designations that have been granted to the emerging drugs?
- Eisai
- Biogen
- Changchun Huayang High-tech Co. Ltd.
- Hoffmann-La Roche
- vTv Therapeutics
- AZTherapies
- Cerecin
- Neurotrope
- Lyndra
- AC Immune
- INmune Bio
- Cassava Sciences
- EIP Pharma
- Neuraly
- AB Science
- Cortexyme
- Anavex Life Sciences
- Athira Pharma
- Time Therapeutics
- Prilenia Therapeutics
- Denali Therapeutics Inc.
- BAN2401
- Elenbecestat (E2609)
- Octohydroaminoacridine Succinate
- Gantenerumab
- Azeliragon (TTP488)
- ALZT-OP1
- AZT-211
- Tricaprilin
- Bryostatin-1
- Donepezil/memantine extended release
- ACI-3024
- INB03
- Sumifilam
- Neflamapimod
- Pegylated exenatide
- Masitinib
- Atuzaginstat
- Blarcamesine
- NDX-1017
- Bromocriptine
- Pridopidine
- DNL788
Introduction
Executive Summary
Alzheimer’s Disease (AD): Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Alzheimer’s Disease (AD) – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Alzheimer’s Disease (AD) companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Alzheimer’s Disease (AD) Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
BAN2401: Eisai
Product Description
Research and Development
Product Development Activities
Mid Stage Products (Phase II)
Comparative Analysis
Bryostatin-1: Neurotrope
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I)
Comparative Analysis
INB03 - INmune Bio
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Pre-clinical and Discovery Stage Products
Comparative Analysis
AZT-211: AZTherapies
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Alzheimer’s Disease (AD) Key Companies
Alzheimer’s Disease (AD) Key Products
Alzheimer’s Disease (AD)- Unmet Needs
Alzheimer’s Disease (AD)- Market Drivers and Barriers
Alzheimer’s Disease (AD)- Future Perspectives and Conclusion
Alzheimer’s Disease (AD) Analyst Views
Alzheimer’s Disease (AD) Key Companies
Appendix
Executive Summary
Alzheimer’s Disease (AD): Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Alzheimer’s Disease (AD) – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Alzheimer’s Disease (AD) companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Alzheimer’s Disease (AD) Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
BAN2401: Eisai
Product Description
Research and Development
Product Development Activities
Mid Stage Products (Phase II)
Comparative Analysis
Bryostatin-1: Neurotrope
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I)
Comparative Analysis
INB03 - INmune Bio
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Pre-clinical and Discovery Stage Products
Comparative Analysis
AZT-211: AZTherapies
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Alzheimer’s Disease (AD) Key Companies
Alzheimer’s Disease (AD) Key Products
Alzheimer’s Disease (AD)- Unmet Needs
Alzheimer’s Disease (AD)- Market Drivers and Barriers
Alzheimer’s Disease (AD)- Future Perspectives and Conclusion
Alzheimer’s Disease (AD) Analyst Views
Alzheimer’s Disease (AD) Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Alzheimer’s Disease (AD)
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Alzheimer’s Disease (AD)
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Alzheimer’s Disease (AD)
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Alzheimer’s Disease (AD)
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
